BR112014023405A2 - nanopartícula de derivado de quitosana, composição compreendendo a nanopartícula e método in vitro para distribuir molécula de ácido nucleico a uma célula - Google Patents
nanopartícula de derivado de quitosana, composição compreendendo a nanopartícula e método in vitro para distribuir molécula de ácido nucleico a uma célulaInfo
- Publication number
- BR112014023405A2 BR112014023405A2 BR112014023405A BR112014023405A BR112014023405A2 BR 112014023405 A2 BR112014023405 A2 BR 112014023405A2 BR 112014023405 A BR112014023405 A BR 112014023405A BR 112014023405 A BR112014023405 A BR 112014023405A BR 112014023405 A2 BR112014023405 A2 BR 112014023405A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticle
- cell
- composition
- nucleic acid
- acid molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Materials Engineering (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613885P | 2012-03-21 | 2012-03-21 | |
US61/613,885 | 2012-03-21 | ||
PCT/CA2013/050218 WO2013138930A1 (en) | 2012-03-21 | 2013-03-15 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014023405A2 true BR112014023405A2 (pt) | 2017-06-20 |
BR112014023405B1 BR112014023405B1 (pt) | 2021-08-24 |
Family
ID=49221759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014023405-1A BR112014023405B1 (pt) | 2012-03-21 | 2013-03-15 | Nanopartícula de derivado de quitosana, composição compreendendo a nanopartícula e método in vitro para distribuir molécula de ácido nucleico a uma célula |
Country Status (20)
Country | Link |
---|---|
US (4) | US9623112B2 (pt) |
EP (1) | EP2828332B1 (pt) |
JP (1) | JP6247276B2 (pt) |
KR (2) | KR102223224B1 (pt) |
CN (1) | CN104395391B (pt) |
AU (1) | AU2013234795B2 (pt) |
BR (1) | BR112014023405B1 (pt) |
CA (1) | CA2867888C (pt) |
DK (1) | DK2828332T3 (pt) |
EA (1) | EA032034B1 (pt) |
ES (1) | ES2635990T3 (pt) |
HK (1) | HK1206378A1 (pt) |
IL (1) | IL234682A (pt) |
MX (1) | MX353705B (pt) |
PL (1) | PL2828332T3 (pt) |
PT (1) | PT2828332T (pt) |
SG (1) | SG11201405902PA (pt) |
SI (1) | SI2828332T1 (pt) |
WO (1) | WO2013138930A1 (pt) |
ZA (1) | ZA201407600B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138930A1 (en) | 2012-03-21 | 2013-09-26 | Engene, Inc. | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |
US20160130606A1 (en) * | 2013-06-10 | 2016-05-12 | Polyvalor, Société En Commandite | Freeze-dried polyelectrolyte complexes that maintain size and biological activity |
SG10202112747QA (en) * | 2013-09-25 | 2021-12-30 | Engene Inc | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |
US10786527B2 (en) * | 2015-03-19 | 2020-09-29 | University Of Massachusetts | Nanoparticle-stabilized nanocapsules and methods of preparation and use for nucleic acid delivery |
BR112018008613A2 (pt) | 2015-10-30 | 2018-10-30 | Bonac Corporation | ?composição, e, método para produzir uma composição e para estabilizar uma molécula de ácido nucleico? |
KR101741977B1 (ko) | 2016-04-26 | 2017-05-31 | 한국교통대학교산학협력단 | 경구 투여용 유전자 전달을 위한 나노입자 및 이를 포함하는 약학 조성물 |
CA3043124A1 (en) * | 2016-11-09 | 2018-05-17 | Engene, Inc. | Intestinal expression of programmed death ligand 1 |
US20200069594A1 (en) * | 2016-12-09 | 2020-03-05 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
CN111343970A (zh) | 2017-09-13 | 2020-06-26 | 北卡罗莱纳州立大学 | 微针贴片局部诱导脂肪组织褐变治疗肥胖症 |
CA3090278A1 (en) * | 2018-02-02 | 2019-08-08 | John Mansell | Compositions and methods for treatment of obesity and obesity-related disorders |
EP3543325A1 (en) * | 2018-03-19 | 2019-09-25 | Green Impact Holding AG | Organic disinfecting agent |
CN108773831B (zh) * | 2018-06-11 | 2019-07-02 | 南京师范大学 | L-精氨酸纳米粒子和一氧化氮为动力源的可降解型纳米马达及其制备方法 |
CN112424239B (zh) * | 2018-07-11 | 2023-12-05 | 学校法人常翔学园 | 高分子化合物及使用了该高分子化合物的细胞内化合物导入促进剂 |
US20210395759A1 (en) * | 2018-11-12 | 2021-12-23 | Massachusetts Institute Of Technology | Organelle-selective gene delivery and expression in the chloroplast in planta using chitosan-complexed single-walled carbon nanotube carriers |
CN109358191B (zh) * | 2018-12-07 | 2021-07-09 | 上海荣盛生物药业有限公司 | 用于免疫试剂的组合物及其制备方法 |
JP2022524859A (ja) * | 2019-03-14 | 2022-05-10 | エンジーン,インコーポレイティド | キトサン-核酸ナノ粒子の可逆的コーティング及びその使用方法 |
GB202116867D0 (en) * | 2021-11-23 | 2022-01-05 | Highersteaks Ltd | Methods and compositions for protein expression and cell differentiation |
KR20240087488A (ko) | 2022-11-30 | 2024-06-19 | 한양대학교 산학협력단 | 글라이콜 키토산 및 금 입자를 포함하는 금 나노자임 및 이를 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물 |
CN116693708B (zh) * | 2023-04-28 | 2024-08-30 | 百珍堂生物科技(浙江)有限公司 | 一种高活性鲍鱼内脏多糖及其低共熔溶剂提取方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1226054C (zh) * | 2003-09-02 | 2005-11-09 | 天津大学 | 壳聚糖-精氨酸缀合物抗凝血材料的制备方法 |
US8119780B2 (en) | 2006-06-02 | 2012-02-21 | Synedgen, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
KR100825519B1 (ko) * | 2007-01-05 | 2008-04-25 | 주식회사 바이오폴리메드 | 키토산 기재 고분자 접합체 및 그 제조방법 |
PT2195035T (pt) * | 2007-09-28 | 2018-03-07 | Engene Inc | Composições de poliplexos de ácido nucleico de quitosano de alta concentração |
CN101195031B (zh) * | 2007-12-20 | 2011-04-20 | 上海交通大学 | 葡萄糖酸改性壳聚糖亲核no供体及其合成方法 |
EP2391387A1 (en) | 2009-01-29 | 2011-12-07 | Synedgen, Inc. | Nucleic acid delivery using modified chitosans |
CN101759812A (zh) * | 2009-12-28 | 2010-06-30 | 中国药科大学 | 一种新型仿穿膜肽结构的壳聚糖衍生物 |
WO2012105685A1 (ja) | 2011-02-04 | 2012-08-09 | 国立大学法人九州大学 | キトサン誘導体から得られるヒドロゲル |
WO2013138930A1 (en) | 2012-03-21 | 2013-09-26 | Engene, Inc. | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |
-
2013
- 2013-03-15 WO PCT/CA2013/050218 patent/WO2013138930A1/en active Application Filing
- 2013-03-15 EA EA201401041A patent/EA032034B1/ru unknown
- 2013-03-15 ES ES13763497.8T patent/ES2635990T3/es active Active
- 2013-03-15 PL PL13763497T patent/PL2828332T3/pl unknown
- 2013-03-15 EP EP13763497.8A patent/EP2828332B1/en active Active
- 2013-03-15 MX MX2014011216A patent/MX353705B/es active IP Right Grant
- 2013-03-15 PT PT137634978T patent/PT2828332T/pt unknown
- 2013-03-15 SI SI201330724T patent/SI2828332T1/sl unknown
- 2013-03-15 AU AU2013234795A patent/AU2013234795B2/en active Active
- 2013-03-15 BR BR112014023405-1A patent/BR112014023405B1/pt active IP Right Grant
- 2013-03-15 JP JP2015500723A patent/JP6247276B2/ja active Active
- 2013-03-15 DK DK13763497.8T patent/DK2828332T3/en active
- 2013-03-15 US US14/386,321 patent/US9623112B2/en active Active
- 2013-03-15 KR KR1020207000239A patent/KR102223224B1/ko active IP Right Grant
- 2013-03-15 SG SG11201405902PA patent/SG11201405902PA/en unknown
- 2013-03-15 CA CA2867888A patent/CA2867888C/en active Active
- 2013-03-15 CN CN201380020157.4A patent/CN104395391B/zh active Active
- 2013-03-15 KR KR1020147029498A patent/KR102064142B1/ko active IP Right Grant
-
2014
- 2014-09-16 IL IL234682A patent/IL234682A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07600A patent/ZA201407600B/en unknown
-
2015
- 2015-07-27 HK HK15107128.3A patent/HK1206378A1/xx unknown
-
2017
- 2017-04-17 US US15/489,199 patent/US10456478B2/en active Active
-
2019
- 2019-10-28 US US16/666,310 patent/US11623011B2/en active Active
-
2023
- 2023-03-23 US US18/125,651 patent/US20230414769A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014023405A2 (pt) | nanopartícula de derivado de quitosana, composição compreendendo a nanopartícula e método in vitro para distribuir molécula de ácido nucleico a uma célula | |
BR112014012681A8 (pt) | polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica | |
SG10201607962RA (en) | Artificial nucleic acid molecules | |
BR112014022788A2 (pt) | peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro | |
EP2931319A4 (en) | MODIFIED NUCLEIC ACID MOLECULES AND THEIR USES | |
BR112014030069A2 (pt) | processo para purificar uma composição de ácido furan, e, composição de ácido furan | |
EP2844733A4 (en) | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGICAL CONDITIONS | |
EP3065722A4 (en) | Nucleic acid nanostructures for in vivo agent delivery | |
LT3222952T (lt) | Injekcinių kompozicijų, ypač farmacinių kompozicijų, džiovinimo šaldant būdas ir sistema | |
HUE038664T2 (hu) | Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása | |
SG11201407857SA (en) | Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt | |
IL250370A0 (en) | Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals | |
IL249826A0 (en) | Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations | |
EP2842546A4 (en) | UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION | |
BR112015008951A2 (pt) | composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica | |
CL2015000049A1 (es) | Método y composición para secuestrar arsénico. | |
ZA201407655B (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
HK1187335A1 (en) | Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals 3-- | |
HK1210941A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
IL228705A (en) | Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them | |
EP2814960A4 (en) | USE OF IDED NANOSTRUCTURES IN NUCLEIC ACID TECHNOLOGY | |
BR112014029232A2 (pt) | composição cosmética, processo para preparar uma composição e processo cosmético | |
EP2805956A4 (en) | GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | |
EP2874987A4 (en) | ALPHA AND GAMMA TRUXILLINIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
EP2900923A4 (en) | NETWORK OF AERODYNAMIC PROFILES WITH AERODYNAMIC PROFILES WHICH HAVE DIFFERENT GEOMETRIES ASSOCIATED WITH GEOMETRIC CLASSES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: ENGENE, INC. (CA) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2013, OBSERVADAS AS CONDICOES LEGAIS. |